17,261 trials
Metastatic Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v8 · Stage IVA Colorectal Cancer AJCC v8
Primary: Progression Free Survival (PFS) — 2.3; 2.2 months
Asthma
Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049
Influenza A
Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181
Advanced Malignancies · Metastatic Cancer
Primary: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 4; 5; 4 Participants
Sickle Cell Disease · Stroke
Primary: Number of Randomized Participants With Central Nervous System Complications — 1; 4 Participants — p=0.2914
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per RECIST 1.1 — 0.395; 0.404 proportion of participants — p=0.2176
Xerostomia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants
Pancreatic Cancer · Pancreas Adenocarcinoma · Advanced Pancreatic Cancer
Primary: Progression- Free Survival at 6 Months From Initiation of Trial Treatment — 0; 2 Participants — p=.31
Graft Versus Host Disease · Leukemia · Myelodysplastic Syndromes
Primary: Response to Therapy — 1; 0; 27; 4 Participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Leber's Congenital Amaurosis
Primary: Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes — 6; 5 Participants
Multiple Myeloma
Primary: Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 7; 4; 5 Participants
Colorectal Cancer · Metastatic Cancer
Primary: Objective Response — 1; 3; 2 Participants
Epidermolysis Bullosa
Primary: Number of Patients Who Achieve at Least a 3-point Reduction in AI-NRS. — 1; 3 Participants — p=0.59
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Relapse/Progression Rate at Two Years — 20 percentage of cumulative incidence